Streetbeat News

MDRX

Veradigm Inc

https://www.allscripts.com/

CEO

Paul Black

Employees

6,445

Industry

Computer Systems Design Services

allscripts (nasdaq: mdrx) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. our innovative solutions connect people, places and data across an open, connected community of health™. connectivity empowers caregivers to make better decisions and deliver better care for healthier populations. to learn more, visit www.allscripts.com, twitter, youtube and blog.allscripts.com.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

TD Cowen analyst Charles Rhyee maintains a Buy rating on Veradigm (OTC:MDRX) but lowers the price target from $26 to $15.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 3:41 pm

Deutsche Bank analyst George Hill downgraded Veradigm (OTC:MDRX) from Buy to Hold and reduced the price target from $15 to $10.

Portfolio Pulse from Benzinga Newsdesk

March 19, 2024 | 10:00 am

Sprinklr will replace Veradigm in the S&P SmallCap 600 before trading opens on March 4, 2024, due to Veradigm's suspension from the Nasdaq on February 29 for not complying with listing rules.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 10:19 pm

Veradigm's stock price has decreased following the announcement of its acquisition of ScienceIO. The acquisition indicates a strategic move by Veradigm to expand its data analytics capabilities.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 2:28 pm

In Tuesday's pre-market session, health care stocks saw significant movements. Janux Therapeutics and Viking Therapeutics led the gainers with over 90% increases in their stock prices, while NRX Pharmaceuticals and Veradigm were among the top losers, experiencing over 20% declines. Notably, TransMedics, Ligand Pharmaceuticals, and Hims & Hers Health reported their Q4 earnings, influencing their stock movements.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 1:06 pm

Veradigm has entered into a definitive agreement to acquire ScienceIO for a purchase price of $140M in cash. The deal will be funded through cash on hand without the need for financing. Approximately $44M of the purchase price is deferred, payable over the first three anniversaries of the closing. Veradigm has also reaffirmed its fiscal 2023 financial projections.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 12:28 pm

Veradigm announced it will not meet Nasdaq's deadline of February 27, 2024, for filing required financial statements, risking suspension of trading. The company is working to file the necessary documents and has adopted a stockholder rights plan in anticipation of potential trading suspension.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 12:25 pm

Today's session highlighted significant options activity in the Health Care sector, with notable trades in stocks like MDRX, IBRX, ABT, BCRX, TEVA, TMO, TGTX, CI, MRK, and HUM. The activity ranged from bullish to bearish sentiments across various expiration dates and strike prices, indicating diverse market expectations and strategies among investors.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 5:35 pm

Veradigm Inc. (NASDAQ:MDRX), in partnership with the American College of Cardiology (ACC), has launched TRANSFORM VAX, an initiative aimed at improving cardiovascular health through increased influenza vaccination education. The initiative leverages Veradigm's healthcare data and technology solutions to deliver ACC-sponsored vaccination education messaging to cardiology practices. This effort is supported by the CDC/HHS and seeks to address the implementation gaps in influenza vaccination for patients with cardiovascular disease, which is associated with a significantly lower risk of adverse cardiovascular events.

Portfolio Pulse from Benzinga Newsdesk

February 13, 2024 | 1:14 pm

RBC Capital analyst Sean Dodge has maintained an Outperform rating on Veradigm (NASDAQ:MDRX) but has cut the price target from $22 to $11.

Portfolio Pulse from Benzinga Newsdesk

January 19, 2024 | 2:06 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.